Treatment A (n= 22) | Treatment B (n= 18) | |
---|---|---|
Baseline | ||
Age (years) | 59.5 (58.0 to 67.0) | 56.0 (42.0 to 73.0) |
Women | 16 (73%) | 13 (72%) |
Menopause | 14 (88%) | 8 (62%) |
Current or previous smoker | 15(68%) | 7 (41%) |
Disease duration (months) | 5.4 (2.9) | 4.9 (3.4) |
Rheumatoid factor positivity | 11 (50%) | 10 (56%) |
X-ray criteria at baseline | 7 (32%) | 2 (11%) |
3-month visit | ||
Erythrocyte sedimentation rate (mm) | 25.0 (14.0 to 29.0) | 23.5 (12.0 to 34.0) |
Disease Activity Score of 28 joints | 4.3 (4.1 to 4.9) | 4.8 (3.7 to 5.1) |
HAQ score | 0.86 (0.50) | 0.89 (0.18) |
Leptin (μg/l) | 8.8 (5.4 to 27.7) | 7.9 (3.9 to 14.2) |
Adiponectin (mg/l) | 10.7 (3.4) | 10.9 (6.6) |
Apolipoprotein A1 (g/l) | 1.46 (0.25) | 1.64 (0.23) |
Apolipoprotein B (g/l) | 1.10 (0.26) | 1.03 (0.21) |
Apolipoprotein B/apolipoprotein A1 | 0.77 (0.24) | 0.64 (0.15) |
P1NP (μg/l) | 46 (36 to 58) | 43 (32 to 68) |
CTX-1 (pg/ml) | 280 (191 to 368) | 233 (119 to 457) |
1CTP (μg/l) | 4.1 (3.3 to 5.6) | 3.7 (2.9 to 4.9) |
IGF-1 (μg/l) | 145.5 (114.0 to 166.0) | 154.5 (130.0 to 193.0) |
IGF-1 SD scores | -0.09 (1.34) | -0.07 (-0.12) |